FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP normally takes up to 210 days to evaluate a new application.
Estonian: Uue taotluse hindamiseks kulub inimtervishoius kasutatavate ravimite komiteel enamasti 210 päeva.
English: Voraxaze was to be used as an add-on treatment in patients already receiving a medicine, methotrexate, to prevent or treat the toxic effects of methotrexate.
Estonian: Voraxazet kavatseti kasutada täiendava ravina patsientidel, keda ravitakse metotreksaadiga, et vältida või ravida metotreksaadi toksilisi toimeid.
English: The main concerns of the CHMP were related to the manufacture of Voraxaze.
Estonian: Inimtervishoius kasutatavate ravimite komiteele tekitas peamiselt murelikkust Voraxaze tootmine.
English: What was Voraxaze expected to be used for?
Estonian: Milleks kavatseti Voraxazet kasutada?
English: The effects of Voraxaze were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Voraxaze toimet muude katsetega.
English: The active substance in Voraxaze, glucarpidase, is a copy of the naturally-occurring enzyme carboxypeptidase G2. Carboxypeptidase G2 was originally found in a Pseudomonas bacterium.
Estonian: Voraxaze toimeaine glükarpidaas on looduslikult esineva ensüümi karboksüpeptidaas G2 koopia.
English: There are no precautions necessary.
Estonian: Erilisi ettevaatusmeetmeid ei ole vaja.
English: This summary was last updated in March 2012.
Estonian: Kokkuvõtte viimane uuendus: märtsis 2012.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Oxyglobin on 14 July 1999.
Estonian: Euroopa Komisjon väljastas Oxyglobini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 14. juulil 1999.
English: Haemoglobin glutamer 200
Estonian: (Veise) hemoglobiin glutameer-200
English: Oxyglobin should be used for at least 24 hours.
Estonian: Oxyglobini tuleb kasutada vähemalt 24 tundi.
English: Additional studies supported these results, showing that Oxyglobin can take up, transport and release oxygen in animals other than cows.
Estonian: Neid tulemusi toetasid ka täiendavad uuringud, mis näitasid, et Oxyglobin võib siduda, transportida ja vabastada hapnikku ka teistel liikidel peale veiste.
English: In the main study in dogs, 95% of the animals treated with Oxyglobin needed no other type of oxygen-carrying treatment after 24 hours, compared with 32% of the dogs that did not receive any treatment.
Estonian: Koertega läbiviidud põhiuuringus ei vajanud 95% Oxyglobiniga ravitud koertest 24 tunni pärast muud liiki ravi hapniku transportimiseks, võrreldes 32%-ga ravimata jäänud koertest.
English: Oxyglobin is first warmed to 37°C, then given to the dog as 30 ml per kilogram body weight, administered at a rate of up to 10 ml/kg per hour.
Estonian: Oxyglobin soojendatakse kõigepealt temperatuurini 37 °C ja manustatakse siis koerale annuses 30 ml kehamassi kilogrammi kohta kiirusega kuni 10 ml/kg tunnis.
English: This oxygen can then be supplied to tissues such as muscle.
Estonian: Selle hapnikuga võib varustada kudesid, näiteks lihaseid.
English: The study compared the effects of Oxyglobin with no treatment.
Estonian: Uuringus võrreldi Oxyglobini toimet ravi puudumisega.
English: Other common side effects are vomiting, loss of appetite and fever.
Estonian: Muud sagedad kõrvalnähud on oksendamine, isutus ja palavik.
English: Oxyglobin contains bovine haemoglobin glutamer-200 (at a strength of 130 mg/ml), which belongs to a class of medicines having an oxygen-carrying action.
Estonian: Oxyglobin sisaldab veise glutameer-200-hemoglobiini (tugevusega 130 mg/ml), mis kuulub hapnikku transportiva toimega ravimite klassi.
English: This increases the amount of oxygen carried in the blood in the arteries, helping to reduce the symptoms of anaemia.
Estonian: See suurendab arterites verega edasi kanduva hapniku hulka, aidates vähendada aneemia sümptomeid.
English: Oxyglobin does not need to be matched to the dog's blood type.
Estonian: Oxyglobini ei pea sobitama koera vererühmaga.
English: Oxyglobin is intended for a single use only.
Estonian: Oxyglobin on ette nähtud ainult ühekordseks kasutamiseks.
English: The medicine also increased levels of haemoglobin in the blood and improved the dogs' physical condition.
Estonian: Ravim tõstis ka koerte vere hemoglobiinitaset ja parandas nende füüsilist seisundit.
English: The most appropriate dose depends on the severity of the anaemia and how long the dog has been anaemic, as well as the desired duration of the medicine's effect.
Estonian: Sobiv annus valitakse olenevalt aneemia raskusest ja kestusest, samuti ravimi toime soovitud kestusest.
English: The side effects seen with Oxyglobin are caused both by the medicine and by the underlying cause of the anaemia.
Estonian: Oxyglobini kasutamisel täheldatud kõrvalnähud on põhjustatud nii ravimist kui ka aneemia algpõhjusest.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Oxyglobin exceed the risks for the provision of oxygen-carrying support to dogs improving the clinical signs of anaemia for at least 24 hours, independent of the underlying condition, and recommended that Oxyglobin be given a marketing authorisation.
Estonian: Veterinaarravimite komitee otsustas, et Oxyglobini kasulik toime kasutamisel hapniku transportimise toetamiseks koertel aneemia kliiniliste nähtude ravimiseks vähemalt 24 tunni jooksul olenemata aneemia algpõhjusest on suurem kui sellega kaasnevad ohud, ning Oxyglobinile soovitati anda müügiluba.
English: Oxyglobin should not be used in animals that have received Oxyglobin in the past, or in dogs that are at an increased risk of circulatory overload with conditions such as oliguria or anuria (infrequent or no urination) or advanced heart disease.
Estonian: Oxyglobini ei tohi manustada loomadele, kellele on varem manustatud Oxyglobini, samuti koertele, kellel on suurenenud vereringe ülekoormuse oht, näiteks oliguuria (kusevähesus) või anuuria (kuseerituse puudumine) või kaugelearenenud südamehaiguse korral.
English: It contains haemoglobin glutamer-200, which is made from haemoglobin (the protein in red blood cells that carries oxygen around the body) extracted from cows' blood and diluted in a standard solution (Ringer's lactate) used to replace blood volume.
Estonian: See sisaldab glutameer-200hemoglobiini, mis on valmistatud veiseverest eraldatud hemoglobiinist (punalibledes sisalduv valk, mis kannab hapnikku organismis laiali) ja mis lahjendatakse standardseks lahuseks (Ringeri laktaatlahus), mida kasutatakse vere mahu asendamiseks.
English: For a full list of all side effects reported with Oxyglobin, see the Package Leaflet.
Estonian: Oxyglobini kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: What is the risk associated with Oxyglobin?
Estonian: Millised on Oxyglobiniga kaasnevad riskid?
English: For further information, see the Package Leaflet.
Estonian: Üksikasjalikum teave on esitatud pakendi infolehel.
English: Oxyglobin is a solution for infusion (drip into a vein).
Estonian: Oxyglobin on infusioonilahus (veeni tilgutamiseks).
English: A common side effect is ‘circulatory overload' (when the blood fluid leaks out of the blood vessels), which causes tachypnea (rapid breathing), dyspnea (shortness of breath), harsh lung sounds and pulmonary oedema (fluid accumulation in the lungs).
Estonian: Sage kõrvalnäht on vereringe ülekoormus (verd immitseb veresoontest), mis põhjustab tahhüpnoed (sage hingamine), düspnoed (raskendatud hingamine), kopsukahinaid ja kopsuturset (vedeliku kogunemine kopsudesse).
English: Other information about Oxyglobin:
Estonian: Muu teave Oxyglobini kohta
English: Oxyglobin is a haemoglobin-based oxygen-carrying solution.
Estonian: Oxyglobin on hemoglobiinil põhinev hapnikku transportiv lahus.
English: When Oxyglobin is given to dogs, it increases the amount of haemoglobin in the blood, as well as increasing the volume of blood in the body.
Estonian: Oxyglobini manustamisel koertele suureneb vere hemoglobiinisisaldus ning vere maht organismis.
English: Oxyglobin has been tested in a study of dogs with short or long-term anaemia due to conditions such as blood loss, the abnormal breakdown of red blood cells or low levels of red blood cell production.
Estonian: Oxyglobini kasutamist uuriti lühi- või pikaajalise aneemiaga koertega läbi viidud uuringus, kelle aneemia oli põhjustatud verekaotusest, punaliblede lagunemise häiretest või punaliblede vähesest tekkest.
English: Oxyglobin is used to increase the oxygen content of the blood in dogs with anaemia (low red blood cell count).
Estonian: Oxyglobini kasutatakse vere hapnikusisalduse suurendamiseks aneemiaga (vere punaliblede vähesusega) koertel.
English: Why has Oxyglobin been approved?
Estonian: Miks Oxyglobin heaks kiideti?
English: They include discoloration of the skin, mucous membranes (lining of body cavities) and sclera (whites of the eyes), dark faeces and discoloured or turbid (opaque) urine.
Estonian: Need on muu hulgas naha, limaskestade ja kõvakesta (silmavalge) värvimuutus, rooja tumenemine ja uriini värvimuutus või hägunemine.
English: What is Oxyglobin?
Estonian: Mis on Oxyglobin?
English: What is Oxyglobin used for?
Estonian: Milleks Oxyglobini kasutatakse?
English: How does Oxyglobin work?
Estonian: Kuidas Oxyglobin toimib?
English: It took longer until additional treatment was needed in dogs treated with Oxyglobin.
Estonian: Oxyglobiniga ravitud koertel kulus kauem aega täiendava ravi vajaduse tekkimiseni.
English: What benefit has Oxyglobin shown during the studies?
Estonian: Milles seisneb uuringute põhjal Oxyglobini kasulikkus?
English: How has Oxyglobin been studied?
Estonian: Kuidas Oxyglobini uuriti?
English: 1 vial l t o r
Estonian: Intravenoosne Viaal (klaasist) 1 viaal l n a
English: The recommended dose is 0.25 mg given every 24 hours, either in the morning or in the evening.
Estonian: Soovitatav annus on 0,25 mg iga 24 tunni tagant, kas hommikul või õhtul.
English: Further information on Cetrotide can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/cetrotide.
Estonian: Lisateave Cetrotide kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/cetrotide.
English: Cetrotide received a marketing authorisation valid throughout the EU on 13 April 1999.
Estonian: Cetrotide on saanud müügiloa, mis kehtib kogu ELis, 13. aprillil 1999.
English: What measures are being taken to ensure the safe and effective use of Cetrotide?
Estonian: Mis meetmed võetakse, et tagada Cetrotide ohutu ja efektiivne kasutamine?
English: Other information about Cetrotide
Estonian: Muu teave Cetrotide kohta
English: The European Medicines Agency therefore decided that Cetrotide's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Cetrotide kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Cetrotide (cetrorelix)
Estonian: Cetrotide (tsetroreliks)
English: As for all medicines, data on the use of Cetrotide are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Cetrotide kasutamise kohta pidevat järelevalvet.
English: What is Cetrotide and what is it used for?
Estonian: Mis on Cetrotide ja milleks seda kasutatakse?
English: The medicine should be injected slowly at different places on the abdomen every day.
Estonian: Ravimit tuleb süstida iga päev aeglaselt kõhu eri piirkonda.
English: Why is Cetrotide authorised in the EU?
Estonian: Miks Cetrotide ELis heaks kiideti?
English: Because of the risk of severe allergic reactions, the first injection should be supervised by a doctor, and the patient closely watched for 30 minutes.
Estonian: Raskete allergiareaktsioonide riski tõttu tuleb esimene süst teha arsti juuresolekul ja seejärel patsienti hoolikalt jälgida 30 minuti jooksul.
English: Side effects reported with Cetrotide are carefully evaluated and any necessary action taken to protect patients.
Estonian: Cetrotide kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Further injections may be given by the patient herself, as long as she is made aware of the signs of allergic reaction and what to do if they appear.
Estonian: Järgmisi süste võib patsient teha ise, kui ta teab allergilise reaktsiooni sümptomeid ja mida nende esinemise korral teha.
English: For more information about using Cetrotide, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Cetrotide kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cetrotide have been included in the summary of product characteristics and the package leaflet.
Estonian: Cetrotide ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Sudden, severe allergic reactions have been reported with Cetrotide and may affect between 1 and 10 patients in 1,000.
Estonian: Cetrotidega on teatatud äkilistest rasketest allergilistest reaktsioonidest, mis võivad esineda 1-10 patsiendil 1000st.
English: Cetrotide can only be obtained with a prescription and treatment should be carried out by a doctor who has experience in this type of fertility treatment.
Estonian: Cetrotide on retseptiravim ja ravi peab teostama seda tüüpi viljatusravi kogemusega arst.
English: The studies involved 814 women and compared Cetrotide with buserelin nasal spray and triptorelin depot injection.
Estonian: Uuringutes osales 814 naist ja neis võrreldi Cetrotidet busereliini ninapihuse ja triptoreliini depoosüstega.
English: Results showed that between 95 and 97% of the patients receiving Cetrotide had no LH surge, compared with 98% for buserelin and 97% for triptorelin.
Estonian: Patsiente, kellel LH teke järsult ei suurenenud, oli Cetrotide uuringurühmas 95-97%, busereliini rühmas 98% ja triptoreliini rühmas 97%.
English: Treatment starts usually on day 5 or 6 of ovarian stimulation, continued throughout the ovarian stimulation period, until the evening before or the morning of the day when the induction of ovulation (the release of eggs) is planned.
Estonian: Ravi algab tavaliselt munasarjastimulatsiooni 5. või 6. päeval ning jätkub kogu munasarjastimulatsiooni vältel kuni kavandatud tekitatava ovulatsiooni (munarakkude munasarjast eraldumise) päeva eelõhtu või hommikuni.
English: It must not be used in women who are pregnant or breastfeeding, or in patients with severe kidney disease.
Estonian: Cetrotidet ei tohi kasutada rasedad ega imetavad naised ega raske neeruhaigusega patsiendid.
English: Cetrotide is an effective alternative to existing treatments for the prevention of premature ovulation and its side effects are manageable.
Estonian: Cetrotide on enneaegse ovulatsiooni ennetamise olemasolevate meetodite tõhus alternatiiv ja selle kõrvanähud on ohjatavad.
English: How does Cetrotide work?
Estonian: Kuidas Cetrotide toimib?
English: What are the risks associated with Cetrotide?
Estonian: Mis riskid Cetrotidega kaasnevad?
English: For the full list of side effects and restrictions with Cetrotide, see the package leaflet.
Estonian: Cetrotide kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Cetrotide must not be used in people who are hypersensitive (allergic) to any hormones that are chemically similar to gonadotropin-releasing hormone, or to extrinsic peptide hormones (hormone medicines similar to Cetrotide).
Estonian: Cetrotidet ei tohi kasutada patsiendid, kes võivad olla gonadotropiini vabastava hormooni sarnase struktuuriga mis tahes hormoonide või väliste peptiidhormoonide (Cetrotidega sarnased hormoonravimid) suhtes ülitundlikud (allergilised).
English: The most common side effects with Cetrotide (which may affect between 1 and 10 patients in 100) are mild to moderate overstimulation of the ovaries (which can occur as a side effect of the ovarian stimulation procedure itself) and reactions at the injection site, such as redness, swelling and itching.
Estonian: Cetrotide kõige sagedamad kõrvalnähud (võivad esineda 1-10 patsiendil 100st) on kerge või mõõdukas munasarjade ülestimulatsioon (võib esineda munasarjastimulatsiooni kõrvalnähuna) ja süstekoha reaktsioonid, näiteks punetus, turse ja sügelus.
English: Once the assisted-reproduction procedure was completed, 23% of patients who received Cetrotide became pregnant, compared with 32% in the comparator groups.
Estonian: Pärast viljatusravi lõpetamist rasestus Cetrotidet saanud naistest 23% ja võrdlusrühmades 32%.
English: By blocking the effect of LHRH, Cetrotide stops the production of LH, and therefore prevents premature ovulation, which can result in the release of eggs that are immature and unsuitable for use in techniques such as in vitro fertilisation (IVF).
Estonian: LHRH toimet blokeerides takistab Cetrotide LH teket ning ennetab niiviisi enneaegset ovulatsiooni, millega võib kaasneda ebaküpsete ja tehisviljastamiseks (IVF) sobimatute munarakkude eraldumine.
English: LHRH controls the production and release of another hormone called luteinising hormone (LH), which causes ovulation.
Estonian: LHRH reguleerib teise hormooni, luteiniseeriva hormooni (LH) tekkimist ja vabanemist, mis põhjustab ovulatsiooni.
English: In three main studies, Cetrotide was as effective as the comparator treatments in preventing a surge in the production of LH.
Estonian: Cetrotide oli kolmes põhiuuringus LH tekke järsu suurenemise takistamisel sama efektiivne kui võrdlusravimid.
English: How is Cetrotide used?
Estonian: Kuidas Cetrotidet kasutatakse?
English: It is given to women having ovarian stimulation (fertility treatment where the ovaries are stimulated to produce more eggs).
Estonian: Cetrotidet manustatakse naistele, kes saavad munasarjastimulatsiooni (viljatusravi, mille korral stimuleeritakse munasarju eraldama rohkem munarakke).
English: Cetrotide is a medicine used to prevent premature ovulation (early release of eggs from the ovary).
Estonian: Cetrotidet kasutatakse enneaegse ovulatsiooni (munaraku varane eraldumine munasarjast) ennetamiseks.
English: What benefits of Cetrotide have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cetrotide kasulikkus?
English: During fertility treatment, ovarian stimulation is used to make the ovaries produce more eggs.
Estonian: Viljatusravi ajal stimuleeritakse munasarju eraldama rohkem munarakke.
English: The active substance in Cetrotide, cetrorelix, blocks the effects of luteinising-hormone-releasing hormone (LHRH) in the body.
Estonian: Cetrotide toimeaine tsetroreliks blokeerib organismi loodusliku hormooni - luteiniseerivat hormooni vabastava hormooni (LHRH) - toime.
English: These medicines also act on the secretion of LH, but work by overstimulating the production of LHRH, so that the body in response reduces and stops making LH.
Estonian: Mõlemad ravimid mõjutavad samuti LH teket, kuid ülestimuleerivad LHRH teket, nii et LH teke väheneb, kuni organismis LH-d enam ei teki.
English: An overview of Cetrotide and why it is authorised in the EU
Estonian: Ülevaade ravimist Cetrotide ja ELis müügiloa väljastamise põhjendus
English: Cetrotide contains the active substance cetrorelix.
Estonian: Ravim sisaldab toimeainena tsetroreliksi.
English: Cetrotide is given by injection under the skin of the lower abdomen (belly).
Estonian: Cetrotidet manustatakse nahaaluse süstena alakõhtu.
English: PritorPlus with food and alcohol
Estonian: PritorPlus koos toidu ja alkoholiga
English: If you feel dizzy or tired, do not drive or operate machinery.
Estonian: Kui te tunnete pearinglust või väsimust, siis ärge autot juhtige ega käsitsege masinaid.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 April 2002
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV Müügiloa esmase väljastamise kuupäev: 22. aprill 2002
English: The tablets should be swallowed with some water or other nonalcoholic drink.
Estonian: Tabletid tuleb võtta koos vee või mõne muu mittealkohoolse joogiga.
English: This applies especially to the medicines listed below taken at the same time with PritorPlus:
Estonian: See käib eriti allpool loetletud ravimite kohta, kui neid kasutatakse samaaegselt PritorPlus'iga:
English: Elderly Pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years.
Estonian: Eakad Telmisartaani farmakokineetika ei erine alla 65aastastel ja vanemaealistel inimestel.
English: See also information under the heading “Do not take PritorPlus”.
Estonian: Vt ka teavet pealkirja all “Ärge võtke PritorPlus'i”).
English: Date of latest renewal: 14 May 2007
Estonian: Müügiloa viimase uuendamise kuupäev: 14. mai 2007
English: You can take PritorPlus with or without food.
Estonian: Te võite PritorPlusi võtta koos toiduga või ilma.
English: If you do not take your tablet on one day, take your normal dose on the next day.
Estonian: Kui unustate ühel päeval ravimit võtta, võtke järgmisel päeval tavaline annus.
English: What PritorPlus is and what it is used for
Estonian: Mis on PritorPlus ja milleks seda kasutatakse
English: Possible side effects of PritorPlus:
Estonian: PritorPlus'i võimalikud kõrvaltoimed:
English: PritorPlus can have influence on the ability to drive and use machines.
Estonian: PritorPlus võib mõjutada autojuhtimise ja masinate käsitsemise võimet.
English: • if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6).
Estonian: • kui olete telmisartaani või selle ravimi mis tahes koostisosa(de) (loetletud lõigus 6) suhtes allergiline;
English: Other medicines and PritorPlus:
Estonian: Muud ravimid ja PritorPlus
English: The safety and efficacy of PritorPlus in children and adolescents aged below 18 have not been established.
Estonian: PritorPlus'i ohutus ja efektiivsus lastel ja alla 18-aastastel noorukitel ei ole tõestatud.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/02/215/015-021
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/02/215/015-021
English: Remove your PritorPlus tablet from the blister only directly prior to intake.
Estonian: Eemaldage oma PritorPlus'i tablett blisterpakendist alles vahetult enne selle võtmist.
English: Some people feel dizzy or tired when taking PritorPlus.
Estonian: Mõned inimesed tunnevad PritorPlus'i võtmise ajal pearinglust või väsimust.
English: What PritorPlus contains
Estonian: Mida PritorPlus sisaldab
English: The maximum reduction in blood pressure is generally attained 4-8 weeks after the start of treatment and is sustained during long-term therapy.
Estonian: Maksimaalne vererõhku langetav toime saabub tavaliselt 4...8 nädala jooksul pärast ravi alustamist ja püsib pikaajalise ravi jooksul.
English: PritorPlus contains milk sugar (lactose) and sorbitol.
Estonian: PritorPlus sisaldab piimasuhkrut (laktoosi) ja sorbitooli.
English: These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking PritorPlus.
Estonian: Need võivad olla teie silma siserõhu tõusu sümptomid ning võivad tekkida tundide kuni nädalate jooksul pärast PritorPlus'i kasutusele võtmist.
English: 14 tablets 28 tablets 30 tablets 56 tablets 90 tablets 98 tablets 28 x 1 tablets
Estonian: 14 tabletti 28 tabletti 30 tabletti 56 tabletti 90 tabletti 98 tabletti 28 x 1 tabletti
English: What PritorPlus is and what it is used for What you need to know before you take PritorPlus How to take PritorPlus
Estonian: Mis ravim on PritorPlus ja milleks seda kasutatakse Mida on vaja teada enne PritorPlus'i võtmist Kuidas PritorPlus'i võtta
English: Your doctor will normally advise you to stop taking PritorPlus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of PritorPlus.
Estonian: Tavaliselt soovitab arst lõpetada PritorPlus'i kasutamise enne rasestumist või niipea kui teile saab teatavaks, et olete rase, ning kirjutab teile PritorPlus'i asemel välja mõne muu ravimi.
English: What PritorPlus looks like and contents of the pack
Estonian: Kuidas PritorPlus välja näeb ja pakendi sisu